TP53 and breast cancer: Because in the present patient group we reanalysed follow-up data, we decided to assess once again the influence of all clinical (patients’ age tumour size, lymph node metastases, grade) and biological features (expression of steroid hormone receptors, cytokeratin 5/6 (CK5/6), HER2, TOPOIIα, Ki-67, P53 and MVD), which were previously studied (Biesaga et al. 2011, 2012) on DFS of breast cancer patients.